Literature DB >> 26270874

Pricing Cancer Drugs: When Does Pricing Become Profiteering?

Hannah L Kushnick1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26270874     DOI： 10.1001/journalofethics.2015.17.8.nlit1-1508

Source DB:  PubMed          Journal:  AMA J Ethics


× No keyword cloud information.
  3 in total

1.  Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.

Authors:  Teppei Matsumoto; Shingo Hatakeyama; Teppei Ookubo; Koji Mitsuzuka; Shintaro Narita; Takamitsu Inoue; Shinichi Yamashita; Takuma Narita; Takuya Koie; Sadafumi Kawamura; Tatsuo Tochigi; Norihiko Tsuchiya; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama
Journal:  Med Oncol       Date:  2017-10-31       Impact factor: 3.064

Review 2.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

3.  Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.

Authors:  Kiu Tay-Teo; André Ilbawi; Suzanne R Hill
Journal:  JAMA Netw Open       Date:  2019-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.